Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Yael L. Maxwell

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Presentation TCT 2019

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

Presenter: Pascal Vranckx

September 28, 2019

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Presentation TCT 2019

Aspirin Variability, Interactions and Impact of Different Formulations

Presenter: Dominick Angiolillo

September 28, 2019

Presentation TCT 2019

Evidence for Chronic Aspirin Use in CV Patients: COMPASS and More

Presenter: Sanjit Jolly

September 28, 2019

Presentation TCT 2019

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Aspirin Use for Primary and Secondary Prevention: Critical Appraisal of What We Know and What We Don't

Presenter: Davide Capodanno

September 28, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

Case Resolution: How Did I Treat and What Happened?

Presenter: Amit Vora

September 26, 2019

Presentation TCT 2019

The Approach to the High Bleeding Risk Patient: The Dos and the Don’ts!

Presenter: Bernard Chevalier

September 26, 2019

Advertisement

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Aspirin Variability, Interactions and Impact of Different Formulations

Evidence for Chronic Aspirin Use in CV Patients: COMPASS and More

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Aspirin Use for Primary and Secondary Prevention: Critical Appraisal of What We Know and What We Don't

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Case Resolution: How Did I Treat and What Happened?

The Approach to the High Bleeding Risk Patient: The Dos and the Don’ts!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content